Three numbers exist at once and none of them is derived from the others. The manufacturer sets a list price. Insurers and pharmacy benefit managers negotiate a rebated net price nobody publishes. Sellers post cash rates aimed at people outside that system. What a patient pays depends on which of those three machines is running, and a telehealth platform adds a fourth layer on top.
List price is a starting point, not a price
Manufacturers publish a wholesale acquisition cost for each presentation. It functions as the reference from which everything else is discounted, and almost nobody pays it. Its practical importance is that coinsurance and deductible phases are frequently calculated from a figure anchored to list rather than to whatever the plan actually pays after rebates, which is why an insured patient early in a plan year can face a bill close to the sticker.
List price is also set per presentation. Tirzepatide reaches patients under two brand names from the same manufacturer, Mounjaro carrying a type 2 diabetes indication and Zepbound carrying chronic weight management and obstructive sleep apnea indications. Same molecule, different products, separately priced, with separate channels available to each.
Net price is negotiated and invisible
Between list and what a plan pays sits a rebate arrangement negotiated by a pharmacy benefit manager. Formulary placement is traded for rebate value, which is why two employers with identical drug lists can hold very different economics behind the scenes. None of that is disclosed to the patient, and none of it appears on a receipt.
What patients feel from this layer is placement rather than price. A specialty tier with coinsurance behaves completely differently from a preferred tier with a flat copay, and a step therapy requirement can add weeks before either applies.
Cash rates are set independently
On the cash side, a few reference points are published openly. Manufacturer channels post their self-pay figures, discount platforms surface a retail rate that shifts by pharmacy, and a provider like HealthRX keeps a Zepbound cost page next to the branded and compounded routes it describes. Reading several of these together is more useful than anchoring on any one posted number, since each is set by a different party for a different reason.
| Price type | Who sets it | What moves it | Where it shows up |
|---|---|---|---|
| List price | Manufacturer | Product strategy, presentation | Deductible and coinsurance math |
| Net price | PBM and plan negotiation | Rebates, formulary placement | Nowhere visible to patients |
| Manufacturer self-pay rate | Manufacturer direct channel | Commercial strategy, presentation | LillyDirect, NovoCare pharmacy |
| Retail cash rate | Individual pharmacy | Location, acquisition cost, competition | Counter quote, discount platforms |
| Bundled telehealth price | The platform | Product sourced, services included | Published monthly figure |
Presentation and strength do real work
How a product is packaged changes its economics. Single-dose vials and prefilled autoinjectors are different presentations with different manufacturing and distribution costs, and manufacturers price them separately. Direct channels have often used the vial presentation for self-pay offerings while retail pharmacy stocks the pen, which means a cash shopper and an insured patient may not even be buying the same physical item.
Strength matters differently depending on the seller. Branded products in this class typically carry one price across strengths, so titration does not raise the bill. Compounded preparations priced by milligram behave the opposite way. That single structural difference decides whether a starting-dose quote predicts a maintenance-dose bill.
Pharmacy-to-pharmacy variation is real and local
Two pharmacies a mile apart can quote materially different cash prices for an identical package. Acquisition cost through a wholesaler, local competition, and whatever margin the pharmacy has decided to accept all feed into that number, and none of it is regulated or published. Discount platforms add another layer by negotiating rates that vary by chain and by postal code.
The consequence for a shopper is that a cash quote is a quote for one pharmacy on one day. It is not a market price, and it is worth re-checking when a refill has to be moved because of a stock shortage.
What a telehealth platform adds on top
A platform sells clinical access, and that fee is set by the platform rather than by any pricing system upstream. Ro charges for that access through a membership while the medication is billed by whichever pharmacy dispenses it, so the total is a sum of two independently set numbers. Programs such as Found and Noom built comparable subscription layers around coaching and prescribing.
A different structure quotes one figure covering clinical time and medication together. Henry Meds, Hims and Hers, and FormBlends price that way, which makes forecasting simple because there is only one number to track. What sits underneath is usually a compounded preparation rather than branded product. Compounded medication is prepared by a pharmacy rather than manufactured under an approved application, so it is not FDA-approved, and federal compounding policy restricts preparing copies of commercially available drugs. The lower figure reflects a different product and a different supply chain, not a better negotiation.
Why quoted figures go stale so fast
Every layer above moves on its own schedule. Manufacturers revise list prices and self-pay offerings. Plans redo formularies at the plan year. Pharmacies adjust cash rates without notice. Telehealth platforms run promotional pricing with end dates. A specific dollar figure attached to a named provider is accurate for as long as none of those parties changes anything, which in this category has not been very long. The structure holds; the numbers require checking at the source on the day of purchase.
Frequently asked questions
Why does an insured patient sometimes pay more than the cash price?
Because cost share during a deductible phase is often calculated from a list-anchored figure, while a cash rate is set independently to attract self-pay buyers. The two numbers come from unrelated processes, so either can be higher. Asking a pharmacy for both figures at every fill is the only reliable check.
Does the same drug cost the same at every pharmacy?
Not for cash buyers. Wholesale acquisition cost, local competition and pharmacy margin all vary, and none of it is published. Insured pricing is more consistent within a plan because the benefit manager contract governs it, but network status still changes what an out-of-network pharmacy can charge.
Why are vials and pens priced differently?
They are separate presentations with different production and distribution economics, and manufacturers price and distribute them separately. Direct self-pay channels have often used vials while retail stocks autoinjectors, so a cash quote and an insured quote may describe different physical products.
Do rebates reach the patient?
Rarely in a visible way. Rebates flow between manufacturers, benefit managers and plan sponsors, and the patient’s cost share is frequently calculated before they are applied. Some plans have moved to point-of-sale rebate designs, but that remains the exception rather than the default.
Is a lower price ever a warning sign?
It is a signal to check what is being sold. Large gaps in this category usually indicate a compounded preparation rather than an approved product, or a bundled figure that excludes labs and follow-up. Establish the product and the included services before treating a gap as a saving.
